| 摘要 |
FIELD: medicine.SUBSTANCE: patients are examined for the intracellular levels of cardiac protein troponin T (cTnT) or cardiac protein troponin I (cTnl) in the cardiac tissue. The values appearing to be reduced by min. 50% in relation to the control and normal values is a sign of the cardiac involvement in the patient. The method of treating involves detecting the patients with the cardiac involvement by the declared method and introducing the therapeutically effective amount of GGF2 and a proteasome inhibitor. The increasing intracellular levels of the protein cTnT or cTnl in the patient's cardiac tissue after GGF2 has been introduced, are a positive sign of the effective introduction of GGF2 for treating the patient with the cardiac involvement.EFFECT: using the declared group of inventions enables fast and accurate diagnosis of the cardiac involvement in the patient, as well as fast and accurate estimation of the effectiveness of the conducted therapy.19 cl, 26 dwg, 1 ex |
